Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response

BACKGROUND: Given the considerable toxicity and modest benefit of adjuvant chemotherapy for non-small cell lung cancer (NSCLC), there is clearly a need for new treatment modalities in the adjuvant setting. Active specific immunotherapy may represent such an option. However, clinical responses have b...

Descripción completa

Detalles Bibliográficos
Autores principales: Rüttinger, Dominik, van den Engel, Natasja K, Winter, Hauke, Schlemmer, Marcus, Pohla, Heike, Grützner, Stefanie, Wagner, Beate, Schendel, Dolores J, Fox, Bernard A, Jauch, K-W, Hatz, Rudolf A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2020458/
https://www.ncbi.nlm.nih.gov/pubmed/17868452
http://dx.doi.org/10.1186/1479-5876-5-43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2020458/
https://www.ncbi.nlm.nih.gov/pubmed/17868452
http://dx.doi.org/10.1186/1479-5876-5-43

Ejemplares similares